RxDoctor Payments Data

Ronald Szabo, MD

Internal Medicine · Bloomfield, CTNPI 1992729040

Payments from drug & device makers

$788in general payments, 2019–2025

Across 34 payments — averaging $23.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$252
  • Novo Nordisk$163
  • GSK$80
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$53
  • AbbVie$46
  • AstraZeneca$35
  • plus $158 from 7 others

What the payments were for

  • Food & beverage$59075%
  • Education$19825%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$788 in reported general payments places this provider in the 75th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$90,735
Medicare patients
203
Services billed
1,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban117$103,340
FarxigaDapagliflozin Propanediol91$94,003
XareltoRivaroxaban75$88,481
JanuviaSitagliptin Phosphate51$75,763
JardianceEmpagliflozin42$68,959
OzempicSemaglutide29$53,706
MounjaroTirzepatide46$53,140
OxycontinOxycodone Hcl24$21,901
RybelsusSemaglutide15$20,686
Breo ElliptaFluticasone/Vilanterol27$13,085
MyrbetriqMirabegron18$12,816
Lagevrio (Eua)Molnupiravir18$6,795
Dexlansoprazole DrDexlansoprazole13$5,728
DapagliflozinDapagliflozin Propanediol11$5,632
Memantine Hcl ErMemantine Hcl26$5,611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$22$103,340117 claims
AstraZenecaFarxiga, Brilinta$35$99,508103 claims
Novo NordiskOzempic, Rybelsus$163$74,39344 claims
Boehringer IngelheimJardiance$29$68,95942 claims
GSKBreo Ellipta$80$13,08527 claims
Astellas Pharma US IncMyrbetriq$252$12,81618 claims
AbbVieSynthroid$46$2,43845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Bloomfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →